Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aficamten in Chinese patients with obstructive hypertrophic cardiomyopathy
NCT06116968Phase 3Completed
- Sponsor
- CORXEL Pharmaceuticals
- Start
- Nov 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aficamten in hypertrophic cardiomyopathy (HCM), sponsored by CORXEL Pharmaceuticals. Primary endpoints: Adverse Events at 2 years, Serious Adverse Events at 2 years and 2 more. Started Nov 2023; status: completed.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06116968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06116968.